0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hemagen Diagnostics
Its shares trade under the ticker HMGN. It has been listed since 4 February 1993. In the fiscal year to 30 September 2012, it reported revenue of $4.0m and a net loss of $907,315. At that date it held total assets of $2.4m and shareholders' equity of −$3.6m.
Hemagen Diagnostics, Inc. is a biotechnology company. The company is headquartered in Columbia, Maryland. The firm is primarily focused on Veterinary Clinical Diagnostics. The company is also focused on VIRGO, its Human Clinical Diagnostic line of autoimmune and infectious disease products. Its assays utilize multiple technologies, including Enzyme Linked Immunosorbent Assay (ELISA), immunofluorescence (IFA) and hemagglutination (HA). Its product, HEMASORB NSD, is designed to remove interfering substances with patient sera. Its product, The HEMASORB G REMOVAL Reagent, is developed to remove interfering immunoglobulin (IgG) antibodies from human sera prior to testing for immunoglobulin M (IgM). The company develops, manufactures and markets test kits used to aid in the diagnosis of certain autoimmune and infectious diseases. Its products are used in laboratories, hospitals and blood banks around the world. Its autoimmune products include Hemagen DNA Kit, Hemagen Rheumatoid Factor Kit, VIRGO AMA IgG and VIRGO ANA/Hep-2 IgG.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 4 Feb 1993
- Employees
- 15
- Website
- hemagen.com ↗
Leadership
Pay as last reported
- William HalesChairman of the Board, President, Chief Executive Officer, since 1999$192,348
- M. Robert CampbellChief Financial Officer
- Catherine DavidsonPrincipal Accounting Officer, Controller$110,797
- Dr. Alan CohenIndependent Director
- Edward LutzIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hemagen Diagnostics Inc has several strengths that contribute to its success in the market. One of the key strengths is its innovative and advanced diagnostic technology, which allows for accurate and efficient testing procedures. The company also boasts a highly skilled and experienced team of scientists and researchers, enabling them to develop cutting-edge solutions for diagnostic challenges. Additionally, Hemagen Diagnostics Inc has built a strong reputation for quality and reliability among its customers.
Weaknesses
- Despite its strengths, Hemagen Diagnostics Inc faces certain weaknesses that may hinder its growth potential. One weakness is the company's limited global presence, primarily focusing on a specific region or market segment. This limits their exposure to potential international growth opportunities. Another weakness is the company's dependence on external suppliers for certain critical components, which may pose risks in terms of quality control and supply chain disruptions.
Opportunities
- Hemagen Diagnostics Inc operates in a rapidly evolving healthcare industry, presenting several opportunities for growth and expansion. The increasing demand for accurate and efficient diagnostic tests, driven by factors such as an aging population and rising healthcare awareness, provides a significant market opportunity. Furthermore, advancements in technology offer the chance for Hemagen Diagnostics Inc to develop new products and services that cater to emerging diagnostic needs.
Threats
- Several external factors pose threats to Hemagen Diagnostics Inc's business operations. One of these threats is intensifying competition from both established players and emerging startups in the diagnostic industry. This heightens the need for continuous innovation and differentiation to maintain a competitive edge. Economic fluctuations and healthcare regulatory changes also pose threats, as they can impact the purchasing power of customers and affect the demand for diagnostic products and services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.